Clinical trial · Interventional
Thalidomide in Mucosa Associated Lymphoid Tissue (MALT) Lymphoma Patients
Phase II Trial of Thalidomide (Thalidomide Pharmion) in Patients With Advanced or Relapsed Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT)
NCT00373646CI-TRIAL-00002392completedPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of this study is to evaluate Thalidomide for treatment of disseminated MALT Lymphoma or at relapse following helicobacter pylori (HP) - eradication or chemotherapy or radiation.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| MALT Lymphoma | Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Thalidomide, Pharmion | Drug | — | UNRESOLVED |
Design
Arms and outcomes
Arms (0)
[]Primary outcomes (1)
- measure
- To evaluate the clinical potential of thalidomide to induce objective/histologic responses in patients with MALT lymphoma
- timeFrame
- 6 months
Secondary outcomes (2)
- measure
- To evaluate the safety of thalidomide in this patient population and to evaluate
- timeFrame
- 6 months
- measure
- The impact of thalidomide on progression free survival
- timeFrame
- 12 months
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with histologically confirmed MALT lymphoma with measurable disease (Stage I-IV) * With first or greater relapse after HP-eradication, radiation or chemotherapy * Age \> 18 * Must be able to tolerate therapy and have adequate cardiac, renal and hepatic function * ECOG status \_\< 2 * Must be capable of understanding the purpose of the study and have given written informed consent
References
Publications (0)
Data not yet available
No reference posted for this study.